|
Anti-coagulation therapy following coronary endarterectomy in patient with coronary artery bypass graft
|
Hamid Reza Vafaey   , Mohammad Taghi Salehi Omran , Sadaf Abbaspour , Nadia Banihashem , Ghassem Faghanzadeh Ganji |
| Department of Cardiac Surgery , Ayatollah Rohani Hospital, Babol University of Medical Sciences, Babol , Iran , ghf.ganji@yahoo.com |
|
|
Abstract: (6455 Views) |
Background: Since there is a lack of research on postoperative anticoagulation protocol in patients undergoing coronary artery bypass graft (CABG) / coronary endarterectomy (CE), we recommend a new protocol for anticoagulation in these patients.
Methods: In this double-blind randomized clinical trial study, 52 patients undergoing CABG / CE entered the study and were divided into two groups. In group 1, the patients were given warfarin(international normalized ratio (INR) between 2-3) together with 80 mg aspirin daily for 3 months. In group 2, the patients were given 75 mg plavix daily together with 80 mg aspirin daily for 3 months. We evaluated patients with electrocardiography, echocardiography and checking ceratin phosphokinase MB and troponin I in the several stages. The data were analysed SPSS Version18 software.
Results: There was no significant difference between pre and post-operative Ejection fraction in patients with plavix (P=0.21) and warfarin (P=0.316) regimen. However, wall mrotion score was significantly better in clopidogrel – aspirin patients in late (3 months) post operation (p<0.001).
Conclusions: Since warfarin has serious hemorrhagic complications and requires closed monitoring of serum drug activity by serial INR checking, it is recommended that clopidogrel – aspirin can be the preferred alternative anticoagulation therapy in CABG / CE patients.
|
|
| Keywords: Coronary artery bypass graft, Coronary endarterectomy, Warfarin, Clopidogrel |
|
|
Full-Text [PDF 305 kb]
(1552 Downloads)
|
Type of Study: Original Article |
Subject:
Cardiology
Received: 2017/01/19 | Accepted: 2017/05/7 | Published: 2017/10/18
|
|
|
|
|
|
